LH
LH.US Labcorp Holdings Inc.
- Market cap
- USD 30.1B
- P/E
- 30.4x
- P/B
- 3.40x
- ROE
- 12.6%
- Dividend yield
- 0.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LH.US undervalued?
Graham numberLH.US trades 114.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Labcorp Holdings Inc. fundamental analysis
No fundamental analysis for Labcorp Holdings Inc. yet.
Labcorp Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising…
Full company profileLabcorp Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Labcorp Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.64B | 10.4B | 11.3B | 11.6B | 14.0B | 13.1B | 11.9B | 12.2B | 13.0B | 14.0B | 14.8B |
| Gross Profit | 3.18B | 3.46B | 3.18B | 3.25B | 4.95B | 4.99B | 3.71B | 3.36B | 3.62B | 3.73B | 4.21B |
| Operating Income | 1.31B | 1.36B | 1.33B | 1.33B | 2.45B | 3.05B | 1.44B | 726M | 1.09B | 1.52B | 1.65B |
| EBITDA | 1.82B | 1.85B | 2.06B | 1.92B | 3.05B | 3.68B | 1.95B | 1.35B | 1.81B | 2.01B | 2.32B |
| Net Income | 732M | 1.27B | 884M | 824M | 1.56B | 2.38B | 1.28B | 418M | 746M | 877M | 1.12B |
| EPS | 7.02 | 12 | 8.61 | 8.35 | 16 | 24 | 14 | 4.77 | 8.84 | 10 | 14 |
| Balance Sheet | |||||||||||
| Total Assets | 14.2B | 16.6B | 16.2B | 18.0B | 20.1B | 20.4B | 20.2B | 16.7B | 18.4B | 18.4B | 18.9B |
| Total Liabilities | 8.73B | 9.85B | 9.19B | 10.5B | 10.6B | 10.1B | 10.0B | 8.83B | 10.3B | 9.76B | 10.1B |
| Shareholders' Equity | 5.51B | 6.80B | 6.97B | 7.57B | 9.44B | 10.3B | 10.1B | 7.88B | 8.05B | 8.62B | 8.85B |
| Cash & Short-term Investments | 434M | 317M | 427M | 338M | 1.32B | 1.47B | 321M | 537M | 1.52B | 532M | 262M |
| Total Debt | 5.85B | 6.76B | 6.06B | 7.11B | 6.76B | 6.34B | 6.25B | 5.95B | 7.27B | 7.20B | 6.78B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.18B | 1.46B | 1.31B | 1.44B | 2.14B | 3.11B | 1.96B | 1.33B | 1.59B | 1.64B | 1.60B |
| Capital Expenditure | 279M | 315M | 380M | 400M | 382M | 460M | 482M | 454M | 490M | 435M | 539M |
| Free Cash Flow | 897M | 1.14B | 926M | 1.04B | 1.75B | 2.65B | 1.47B | 874M | 1.10B | 1.21B | 1.06B |
| Ratios | |||||||||||
| ROE | 13.3% | 18.6% | 12.7% | 10.9% | 16.5% | 23.1% | 12.7% | 5.3% | 9.3% | 10.2% | 12.6% |
| ROA | 5.1% | 7.7% | 5.5% | 4.6% | 7.8% | 11.7% | 6.3% | 2.5% | 4.1% | 4.8% | 5.9% |
| Net Profit Margin | 7.6% | 12.1% | 7.8% | 7.1% | 11.1% | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% | 7.6% |
| Debt to Equity | 1.06x | 0.99x | 0.87x | 0.94x | 0.72x | 0.62x | 0.62x | 0.76x | 0.90x | 0.84x | 0.77x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Labcorp Holdings Inc. dividends
- Dividend yield
- 0.80%
- Forward dividend
- 2.88 USD
- Payout ratio
- 27.5%
- Ex-dividend date
- Nov 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 241M | 2.87 | 27.5% |
| 2024 | USD 243M | 2.88 | 32.6% |
| 2023 | USD 254M | 2.90 | 60.8% |
| 2022 | USD 195M | 2.13 | 15.3% |
| 2021 | USD 1.00B | 10 | 42.1% |
| 2020 | USD 152M | 1.55 | 9.7% |
| 2019 | USD 2.40B | 24 | 290.7% |
| 2018 | USD 467M | 4.55 | 52.9% |
| 2017 | USD 3.34B | 32 | 263.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1164:1000 on Jul 3, 2023.
Who owns Labcorp Holdings Inc.
- Insiders 0.56%
- Institutions 99.44%
- Public & others 0.00%
- Shares outstanding 81.2M
- Free float 80.8M
Top funds holding LH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.57M | 3.17% | -1.22% | Sep 2026 |
| Vanguard 500 Index Investor | 2.13M | 2.62% | -2.29% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 1.74M | 2.14% | -2.09% | Sep 2026 |
| Allspring Special Mid Cap Value Inst | 1.28M | 1.57% | -12.78% | Oct 2026 |
| iShares Core S&P 500 ETF | 1.08M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.05M | 1.30% | -0.98% | Sep 2026 |
| Victory Sycamore Established Value R | 1.05M | 1.29% | -27.68% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 984K | 1.21% | -0.25% | Oct 2026 |
| Victory Pioneer A | 928K | 1.14% | -15.66% | Sep 2026 |
| Vanguard MStar Value Index Investor | 773K | 0.95% | -1.36% | Sep 2026 |
| Amundi Fds US Pioneer A USD C | 721K | 0.89% | -16.59% | Sep 2026 |
| Fidelity Low-Priced Stock | 684K | 0.84% | -0.06% | Aug 2026 |
| Invesco S&P 500® Equal Weight ETF | 614K | 0.76% | +0.16% | Oct 2026 |
| Vanguard Windsor II Inv | 594K | 0.73% | -4.58% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 593K | 0.73% | +0.88% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 587K | 0.72% | +4.28% | Sep 2026 |
| JHancock Disciplined Value Mid Cap I | 580K | 0.71% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Value ETF | 506K | 0.62% | -4.62% | Sep 2026 |
| Robeco BP Global Premium Eqs B EUR | 504K | 0.62% | +10.72% | Sep 2026 |
| Hartford Dividend and Growth Y | 487K | 0.60% | -19.75% | Sep 2026 |
Top institutions holding LH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 6.57M | 8.10% | +2.01% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.36M | 6.60% | -0.26% | Jun 2026 |
| Victory Capital Management Inc. | 4.84M | 5.96% | +4.55% | Jun 2026 |
| State Street Corp | 3.91M | 4.81% | +1.15% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.68M | 4.53% | -0.05% | Jun 2026 |
| Boston Partners Global Investors, Inc | 3.05M | 3.76% | +28.83% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 2.24M | 2.75% | +0.47% | Jun 2026 |
| Geode Capital Management, LLC | 2.19M | 2.70% | +0.13% | Jun 2026 |
| Select Equity Group LP | 1.98M | 2.44% | -8.87% | Jun 2026 |
| FMR Inc | 1.90M | 2.35% | +47.85% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.61M | 1.98% | +7.44% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.38M | 1.70% | +0.72% | Sep 2026 |
| JPMorgan Chase & Co | 1.27M | 1.56% | -17.25% | Jun 2026 |
| Amvescap Plc. | 1.24M | 1.52% | -5.97% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 887K | 1.09% | -1.42% | Jun 2026 |
| Northern Trust Corp | 883K | 1.09% | -11.46% | Jun 2026 |
| Wellington Management Company LLP | 856K | 1.05% | -10.80% | Jun 2026 |
| Bank of America Corp | 812K | 1.00% | +12.07% | Jun 2026 |
| NORGES BANK | 810K | 1.00% | -18.05% | Jun 2026 |
| Royal Bank of Canada | 808K | 0.99% | -1.56% | Jun 2026 |
Labcorp Holdings Inc. company profile
- Company name
- Labcorp Holdings Inc.
- Ticker
- LH.US
- Exchange
- USA Stocks
- Listed since
- Mar 29, 1990
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 71,000
- Fiscal year end
- December
- Address
- 531 South Spring Street, Burlington, NC, United States, 27215
- Phone
- 336 229 1127
- Website
- labcorp.com
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc. management
10- Mr. Adam H. SchechterPresident, CEO & Chairman · born 1965
- Ms. Julia A. WangExecutive VP & CFO · born 1971
- Dr. Brian J. Caveney J.D., M.D., M.P.H.Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer · born 1974
- Mr. Jonathan C. Meltzer Ph.D.Executive VP & COO
- Mr. Peter J. WilkinsonSenior VP & Chief Accounting Officer · born 1971
- Mr. Akinbolade Oyegunwa M.B.A., Ph.D.Executive VP and Chief Information & Technology Officer · born 1983
- Mr. Dewey Steadman C.F.A.Senior Vice President of Investor Relations
- Ms. Kathryn Wright KyleExecutive VP, Chief Legal Officer & Corporate Secretary · born 1971
- Ms. Amy B. SummyExecutive VP, Chief Marketing Officer & Consumer Health Lead · born 1966
- Ms. Anita Z. GrahamExecutive VP & Chief Human Resources Officer · born 1971